AZD9592 + osimertinib

AZD9592 + osimertinib is an investigational combination therapy being evaluated in advanced solid tumors, particularly non-small cell lung cancer (NSCLC) with EGFR mutations. AZD9592 is a bispecific antibody-drug conjugate (ADC) that targets both EGFR and c-MET receptors and delivers a cytotoxic payload via topoisomerase I inhibition. Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), approved for the treatment of NSCLC with specific EGFR mutations. The rationale for this combination is to overcome resistance mechanisms to EGFR TKIs by targeting additional oncogenic drivers such as c-MET amplification or secondary EGFR mutations. The combination is currently under investigation in phase 1 clinical trials to assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors harboring relevant molecular alterations[1][2][4][8].

Other names

tilatamig samrotecan